Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) Other Non Operating Income (2020 - 2025)

Historic Other Non Operating Income for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to -$27382.0.

  • Gain Therapeutics' Other Non Operating Income rose 7739.62% to -$27382.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$733134.0, marking a year-over-year decrease of 14025.76%. This contributed to the annual value of $119120.0 for FY2024, which is 12774.45% up from last year.
  • Per Gain Therapeutics' latest filing, its Other Non Operating Income stood at -$27382.0 for Q3 2025, which was up 7739.62% from -$620924.0 recorded in Q2 2025.
  • In the past 5 years, Gain Therapeutics' Other Non Operating Income ranged from a high of $268077.0 in Q1 2024 and a low of -$620924.0 during Q2 2025
  • Its 5-year average for Other Non Operating Income is -$64637.4, with a median of -$27412.0 in 2021.
  • As far as peak fluctuations go, Gain Therapeutics' Other Non Operating Income surged by 72573.41% in 2024, and later plummeted by 132492.2% in 2025.
  • Over the past 5 years, Gain Therapeutics' Other Non Operating Income (Quarter) stood at -$19675.0 in 2021, then plummeted by 911.13% to -$198939.0 in 2022, then plummeted by 105.34% to -$408507.0 in 2023, then skyrocketed by 103.86% to $15758.0 in 2024, then plummeted by 273.77% to -$27382.0 in 2025.
  • Its Other Non Operating Income was -$27382.0 in Q3 2025, compared to -$620924.0 in Q2 2025 and -$100586.0 in Q1 2025.